Kivenul

Ibuprofen and Paracetamol, the active ingredients in Kivenul, are a nonsteroidal anti‑inflammatory drug (NSAID) and an analgesic presented as an oral tablet for oral use. It provides pain relief, reduces fever and alleviates inflammation in adults and children as directed by a healthcare professional.

GNH USA supplies Kivenul as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kivenul combines ibuprofen and paracetamol to address common pain‑related and febrile conditions. - Mild to moderate pain: delivers effective analgesia for headaches, musculoskeletal aches, and dental discomfort. - Fever: lowers elevated body temperature in acute infections or inflammatory states. - Inflammation: reduces swelling and discomfort associated with minor injuries or inflammatory disorders.

Common Side Effects: - Nausea or upset stomach. - Dyspepsia or heartburn. - Headache. - Dizziness. - Mild skin rash. - Elevated liver enzymes.

Serious or Rare Side Effects: - Gastrointestinal bleeding or ulcer perforation. - Severe skin reactions such as Stevens‑Johnson syndrome. - Hepatic failure or severe liver injury. - Acute renal impairment. - Anaphylactic shock. - Cardiovascular events such as myocardial infarction.

Kivenul should be used with caution in the following situations: - Renal impairment: assess kidney function before use. - Active peptic ulcer disease: avoid due to risk of GI bleeding. - Concomitant anticoagulant therapy: monitor for increased bleeding. - Alcohol consumption: limit intake to reduce liver stress. - Liver disease: monitor hepatic function regularly. - Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Kivenul may interact with several medications:

Major Interactions (Avoid): - Warfarin or other anticoagulants: increased risk of bleeding. - Other NSAIDs or corticosteroids: heightened gastrointestinal toxicity. - Lithium or methotrexate: elevated plasma concentrations and toxicity.

Moderate Interactions (Monitor Closely): - Antihypertensive agents (e.g., ACE inhibitors): possible reduction in blood pressure control. - Diuretics: potential for reduced renal perfusion. - Selective serotonin reuptake inhibitors (SSRIs): modest increase in bleeding risk.